Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 3/20 | 0.35 |
| ▸ | USP7 | Q93009 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775027 | 0.87 | USP8 (0.36) | USP8USP7HCRTR2HCRTR1TGFBR1 | |
| SCHEMBL3387027 | 0.87 | USP8 (0.36) | USP8USP7HCRTR2HCRTR1TGFBR1 | |
| SCHEMBL7911719 | 0.84 | HCRTR2 (0.33) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL30775065 | 0.83 | ALDH1A1 (0.39) | HCRTR2HCRTR1TGFBR1GRM5ALDH1A1 | |
| SCHEMBL3388543 | 0.83 | ALDH1A1 (0.39) | HCRTR2HCRTR1TGFBR1GRM5ALDH1A1 | |
| SCHEMBL262916 | 0.81 | CLK4 (0.36) | USP8USP7HCRTR2HCRTR1TDP1 | |
| SCHEMBL16277505 | 0.77 | ALOX15 (0.44) | USP8USP7USP47TGFBR1ALDH1A1 | |
| SCHEMBL3389130 | 0.76 | USP8 (0.38) | USP8USP7L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL17151367 | 0.72 | ALDH1A1 (0.51) | USP8USP7USP47TDP1L3MBTL1 | |
| SCHEMBL18640685 | 0.71 | USP8 (0.42) | USP8USP7TDP1L3MBTL1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| EP-3676261-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Chronos Therapeutics Limited (GB) | 2020-07-08 | — | — | EP | disclosed |
| CN-111315734-A | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019043407-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043407-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | USP8 3174/4885USP7 3579/4885HCRTR2 1/4885 |
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | USP8 4226/4885USP7 4375/4885HCRTR2 1425/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | USP8 3174/4885USP7 3579/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.